SCHEMBL5836151

SCHEMBL5836151

Cn1c(=O)n(-c2ccccc2Cl)c2ccc(C=O)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.41
▸ ALDH1A1 P00352 7/20 0.39
▸ GRM4 Q14833 6/20 0.39
▸ HTT P42858 2/20 0.39
▸ CYP1A2 P05177 3/20 0.38
▸ CYP2C9 P11712 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ CYP2C19 P33261 3/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ENPP2 Q13822 1/20 0.37
▸ CYP2A6 P11509 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ ALDH1A3 P47895 1/20 0.36
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1525859 0.76 ALDH1A1 (0.55) ALDH1A1HTTCYP1A2CYP2C9HPGD
SCHEMBL11281024 0.73 MGLL (0.39) ALDH1A1GRM4CYP2C19MAPTCYP2D6
SCHEMBL24764214 0.70 CYP2A6 (0.45) ALDH1A1HTTCYP1A2CYP2C9HPGD
SCHEMBL18720407 0.69 CYP2A6 (0.50) POLBALDH1A1HTTCYP1A2CYP2C9
SCHEMBL11280367 0.69 KMT2A (0.35) ALDH1A1GRM4CYP2C19MAPTCYP2D6
SCHEMBL8830715 0.67 CYP3A4 (0.50) ALDH1A1GRM4HPGDCYP3A4MAPT
SCHEMBL8830588 0.64 KMT2A (0.49) ALDH1A1GRM4HTTCYP2C19CYP2D6
SCHEMBL5157343 0.64 ALDH1A1 (0.49) ALDH1A1HTTHPGDMAPTCYP2A6
SCHEMBL9711118 0.63 MGLL (0.41) ALDH1A1GRM4CYP2C19MAPTCYP2D6
SCHEMBL28812822 0.62 CYP2A6 (0.54) ALDH1A1HPGDMAPTCYP2A6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056918-B2 Benzimidazole anti-inflammatory compounds PFIZER, INC. (US) 2006-06-06 — — US disclosed
EP-1370557-B1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS PFIZER PROD INC (US) 2005-11-16 — — EP disclosed
EP-1370557-A1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS Pfizer Products Inc. (US) 2003-12-17 — — EP disclosed
US-20030092749-A1 Novel benzimidazole anti-inflammatory compounds PFIZER INC. 2003-05-15 — — US disclosed
WO-2002072576-A1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS PFIZER PRODUCTS INC. (US) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092749-A1 Novel benzimidazole anti-inflammatory compounds MAPK1, JAK1, CNKSR1 POLB 3390/4885ALDH1A1 1806/4885GRM4 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback